Reaction

Coronary Artery Bypass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,704 reports · 104 co-occurring drugs

As of the last recalculation, Coronary Artery Bypass appears in 5,704 FAERS reports alongside 104 co-occurring drug terms. The strongest observed disproportionality signal is RANOLAZINE (PRR 34.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranolazine	96	34.1	34.4
Nitroglycerin	123	8.5	8.6
Clopidogrel	369	7.2	7.2
Metoprolol Tartrate	471	6.8	6.8
Amlodipine Besylate And Benazepril Hydrochloride	17	6.7	6.7
Aspirin	860	6.7	6.7
Ezetimibe And Simvastatin	27	6.5	6.5
Aspirin 81 Mg	799	6.5	6.5
Aspirin 325 Mg	798	6.5	6.5
Isosorbide Dinitrate	34	6.4	6.4
Metoprolol Succinate	146	6.3	6.3
Prasugrel Hydrochloride	17	6.1	6.1
Quinine	13	5.5	5.5
Icosapent Ethyl	12	5.2	5.2
Risankizumab-Rzaa	113	5.1	5.1
Niacin	16	5.0	5.0
Carvedilol	180	5.0	5.0
Atorvastatin Calcium	310	4.8	4.8
Digoxin	90	4.6	4.6
Insulin Human	50	4.6	4.6
Theophylline	14	4.5	4.5
Theophylline Anhydrous	15	4.4	4.4
Losartan Potassium And Hydrochlorothiazide	14	4.4	4.4
Metoprolol Tartrate Injection	222	4.4	4.4
Evolocumab	190	4.4	4.4
Metoprolol	292	4.4	4.4
Gemfibrozil	17	4.1	4.1
Clopidogrel Bisulfate	112	4.1	4.1
Metoroprolol Tartrate	70	3.9	3.9
Insulin Aspart	69	3.8	3.8
Human Insulin	13	3.8	3.8
Glyburide	25	3.8	3.8
Metformin Hcl	56	3.7	3.7
Diltiazem Hydrochloride	35	3.7	3.7
Ezetimibe	74	3.6	3.6
Fluticasone Propionate And Salmeterol	41	3.6	3.6
Sitagliptin	70	3.6	3.6
Lisinopril	287	3.5	3.6
Empagliflozin	64	3.5	3.5
Atenolol	123	3.4	3.4
Furosemide	354	3.4	3.4
Insulin	51	3.4	3.4
Lovastatin	23	3.3	3.3
Quinapril Hydrochloride	7	3.2	3.2
Sitagliptin And Metformin Hydrochloride	19	3.2	3.2
Insulin Glargine	210	3.2	3.2
Rosuvastatin	172	3.1	3.1
Enalapril Maleate	21	3.1	3.1
Insulin Lispro	115	3.1	3.1
Isosorbide Mononitrate	17	3.0	3.0
Meclizine Hcl 12.5Mg	11	2.9	2.9
Meclizine Hcl 25Mg	11	2.9	2.9
Meclizine Hcl 12.5 Mg	11	2.9	2.9
Meclizine Hcl 25 Mg	11	2.9	2.9
Amiodarone Hydrochloride	9	2.9	2.9
Candesartan Cilexetil	21	2.9	2.9
Bumetanide	21	2.9	2.9
Amlodipine Besylate	114	2.9	2.9
Valsartan	82	2.9	2.9
Fluticasone Propionate And Salmeterol Xinafoate	47	2.9	2.9
Losartan Potassium	61	2.8	2.8
Glipizide	47	2.8	2.8
Insulin Degludec	18	2.8	2.8
Pioglitazone	32	2.7	2.7
Simvastatin	180	2.7	2.7
Romiplostim	11	2.7	2.7
Alirocumab	18	2.6	2.6
Terazosin Hydrochloride	6	2.5	2.5
Dolutegravir Sodium	6	2.4	2.4
Darunavir	10	2.4	2.4
Metoprolol Succinate Er Tablets	41	2.4	2.4
Sotalol Hydrochloride	10	2.2	2.2
Relugolix	14	2.2	2.2
Pitavastatin Calcium	6	2.1	2.1
Testosterone Cypionate	5	2.0	2.0
Ibrutinib	44	2.0	2.0
Umeclidinium Bromide And Vilanterol Trifenatate	9	2.0	2.0
Exenatide	27	1.9	1.9
Lisinopril And Hydrochlorothiazide Tablets	4	1.9	1.9
Nintedanib	15	1.7	1.7
Alteplase	7	1.7	1.7
Umeclidinium	4	1.6	1.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	17	1.5	1.5
Darbepoetin Alfa	22	1.5	1.5
Liraglutide	20	1.5	1.5
Leuprolide Acetate	30	1.4	1.4
Upadacitinib	31	1.4	1.4
Oral Semaglutide	27	1.3	1.3
Methoxy Polyethylene Glycol-Epoetin Beta	4	1.3	1.3
Patiromer	5	1.3	1.3
Interferon Beta-1A	69	1.3	1.3
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	3	1.2	1.2
Bosutinib	3	1.2	1.2
Bimekizumab	7	1.2	1.2
Belimumab	10	1.2	1.2
Paricalcitol	4	1.0	1.0
Dasatinib	10	1.0	1.0
Abiraterone Acetate	11	1.0	1.0
Apalutamide	3	0.9	0.9
Guselkumab	8	0.8	0.8
Aflibercept	6	0.7	0.7
Ixekizumab	7	0.7	0.7
Cinacalcet Hydrochloride	8	0.6	0.6
Minoxidil Foam 5% (Womens)	5	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.